Pembrolizumab-induced Myasthenia Gravis: Literature Review of Ocular Manifestations and a Refractory Case-Reference-Cited by-同舟云学术

Pembrolizumab-induced Myasthenia Gravis: Literature Review of Ocular Manifestations and a Refractory Case

Published:2022-05-17 Issue:6 Volume:45 Page:267-273
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:

Author:

Dugena Oliver,Zheng Chaolan,Taylor Jennifer,Wong Annie

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference32 articles.

1. Development of ocular predominant myasthenia gravis after treatment with pembrolizumab for basal cell carcinoma: a case report and literature review;Handa;Remedy Publications LLC,2019

2. Myasthenia triggered by immune checkpoint inhibitors: new case and literature review;Gonzalez;Neuromuscul Disord,2017

3. Neurologic complications of immune checkpoint inhibitors;Fellner;J Neurooncol,2018

4. Immune checkpoint inhibitors (ICIs)-related ocular myositis;Garibaldi;Neuromuscul Disord,2020

5. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients;Nguyen;Melanoma Res,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pembrolizumab-induced myasthenia gravis: Two patients’ experiences;Gynecologic Oncology Reports;2024-08

2. Myasthenia Gravis Associated With Pembrolizumab for Relapsed Lung Cancer After Thymoma Resection;Cureus;2023-12-01

3. PEMBROLIZUMAB-INDUCED MYASTHENIA CRISIS, MYOCARDITIS, MYOSITIS, AND HEPATITIS;CHEST;2023-10

4. Immune checkpoint inhibitors induced side effects of the peripheral nervous system;Current Opinion in Neurology;2023-07-24

5. Current avenues of gene therapy in Pompe disease;Current Opinion in Neurology;2023-07-19